CTLA4 and neoplasm: Although there was no significant difference in the distant tumor volume between the two monotherapies (figure 6C), YST-OVH therapy showed a trend toward a smaller virus-injected tumor volume than anti-CTLA-4 therapy (figure 6B), possibly due to the direct oncolytic effects of YST-OVH in the virus-injected tumors.